A. John Ashcroft

2.7k total citations
23 papers, 1.5k citations indexed

About

A. John Ashcroft is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, A. John Ashcroft has authored 23 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 13 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in A. John Ashcroft's work include Multiple Myeloma Research and Treatments (14 papers), Peptidase Inhibition and Analysis (6 papers) and Bone health and treatments (5 papers). A. John Ashcroft is often cited by papers focused on Multiple Myeloma Research and Treatments (14 papers), Peptidase Inhibition and Analysis (6 papers) and Bone health and treatments (5 papers). A. John Ashcroft collaborates with scholars based in United Kingdom, Australia and United States. A. John Ashcroft's co-authors include Gareth J. Morgan, Faith E. Davies, Roger G. Owen, J. Anthony Child, Mark T. Drayson, Gordon Cook, Sylvia Feyler, Graham Jackson, Walter M. Gregory and Sue Bell and has published in prestigious journals such as The Lancet, Blood and Immunity.

In The Last Decade

A. John Ashcroft

22 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. John Ashcroft United Kingdom	16	949	913	663	190	156	23	1.5k
Marta Krejčí Czechia	17	832 0.9×	574 0.6×	497 0.7×	145 0.8×	190 1.2×	155	1.3k
Sylvia Feyler United Kingdom	16	1.5k 1.6×	1.3k 1.4×	847 1.3×	529 2.8×	191 1.2×	25	2.2k
Evangelos Eleutherakis‐Papaiakovou Greece	24	965 1.0×	739 0.8×	888 1.3×	155 0.8×	288 1.8×	154	1.7k
Miguel‐Teodoro Hernández Spain	14	796 0.8×	544 0.6×	597 0.9×	83 0.4×	210 1.3×	44	1.2k
Carolina Schinke United States	21	899 0.9×	662 0.7×	692 1.0×	215 1.1×	162 1.0×	142	1.4k
Fredrik Schjesvold Norway	16	1.0k 1.1×	809 0.9×	766 1.2×	230 1.2×	121 0.8×	103	1.4k
Nikolaos Kanellias Greece	21	819 0.9×	579 0.6×	710 1.1×	137 0.7×	214 1.4×	132	1.3k
Tommaso Caravita Italy	21	1.8k 1.9×	1.1k 1.2×	1.5k 2.2×	94 0.5×	228 1.5×	69	2.1k
Stephen P. Kahanic United States	15	861 0.9×	772 0.8×	683 1.0×	30 0.2×	195 1.3×	21	1.3k

Countries citing papers authored by A. John Ashcroft

Since Specialization

Citations

This map shows the geographic impact of A. John Ashcroft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. John Ashcroft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. John Ashcroft more than expected).

Fields of papers citing papers by A. John Ashcroft

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. John Ashcroft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. John Ashcroft. The network helps show where A. John Ashcroft may publish in the future.

Co-authorship network of co-authors of A. John Ashcroft

This figure shows the co-authorship network connecting the top 25 collaborators of A. John Ashcroft. A scholar is included among the top collaborators of A. John Ashcroft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. John Ashcroft. A. John Ashcroft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cook, Gordon, A. John Ashcroft, Catherine Olivier, et al.. (2024). Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology. 11(11). e816–e829. 1 indexed citations

McIlroy, Graham, Sylvia Feyler, Rakesh Popat, et al.. (2023). Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic. Blood Cancer Journal. 13(1). 38–38. 8 indexed citations

Snowden, John A., Sam H. Ahmedzai, Angela Cox, et al.. (2022). Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study. Bone Marrow Transplantation. 57(10). 1507–1513.

Striha, Alina, A. John Ashcroft, Anna Hockaday, et al.. (2018). The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials. 19(1). 169–169. 5 indexed citations

Cook, Gordon, A. John Ashcroft, David A. Cairns, et al.. (2016). The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. The Lancet Haematology. 3(7). e340–e351. 96 indexed citations

Ashcroft, A. John, et al.. (2015). Proposed case of mesalazine-induced cardiomyopathy in severe ulcerative colitis. World Journal of Gastroenterology. 21(11). 3376–3379. 10 indexed citations

Cook, Gordon, Cathy Williams, Julia Brown, et al.. (2014). High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. The Lancet Oncology. 15(8). 874–885. 95 indexed citations

Morgan, Gareth J., Faith E. Davies, Walter M. Gregory, et al.. (2012). Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood. 119(23). 5374–5383. 101 indexed citations

Morgan, Gareth J., J. Anthony Child, Walter M. Gregory, et al.. (2011). Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. The Lancet Oncology. 12(8). 743–752. 117 indexed citations

10.

Hill, Quentin A., Richard Kelly, Andy Scally, et al.. (2011). Survival of patients with hematological malignancy admitted to the intensive care unit: prognostic factors and outcome compared to unselected medical intensive care unit admissions, a parallel group study. Leukemia & lymphoma. 53(2). 282–288. 24 indexed citations

11.

Morgan, Gareth J., Faith E. Davies, Walter M. Gregory, et al.. (2010). First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. The Lancet. 376(9757). 1989–1999. 407 indexed citations

12.

Feyler, Sylvia, M von Lilienfeld-Toal, Sarah Jarmin, et al.. (2009). CD4⁺CD25⁺FoxP3⁺ regulatory T cells are increased whilst CD3⁺CD4⁻CD8⁻αβTCR⁺ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. British Journal of Haematology. 144(5). 686–695. 121 indexed citations

13.

Varghese, Abraham, Andy C. Rawstron, A. John Ashcroft, Paul Moreton, & Roger G. Owen. (2009). Assessment of Bone Marrow Response in Waldenström's Macroglobulinemia. Clinical Lymphoma & Myeloma. 9(1). 53–55. 28 indexed citations

14.

Worrillow, Lisa, A. G. Smith, Kathryn Scott, et al.. (2007). Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. Journal of Medical Genetics. 45(3). 142–146. 27 indexed citations

15.

Ashcroft, A. John, Sheena Cruickshank, Peter I. Croucher, et al.. (2003). Colonic Dendritic Cells, Intestinal Inflammation, and T Cell-Mediated Bone Destruction Are Modulated by Recombinant Osteoprotegerin. Immunity. 19(6). 849–861. 129 indexed citations

16.

Ashcroft, A. John, Faith E. Davies, & Gareth J. Morgan. (2003). Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. The Lancet Oncology. 4(5). 284–292. 64 indexed citations

17.

Fenton, James A. L., Guy Pratt, Andy C. Rawstron, et al.. (2003). Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism. Oncogene. 22(7). 1103–1113. 20 indexed citations

18.

Sibley, Kathryn, James A. L. Fenton, Ann Dring, et al.. (2002). A molecular study of the t(4;14) in multiple myeloma. British Journal of Haematology. 118(2). 514–520. 30 indexed citations

19.

Rawstron, Andy C., Faith E. Davies, Ranjit Dasgupta, et al.. (2002). Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 100(9). 3095–3100. 136 indexed citations

20.

Follows, George, et al.. (1999). Eosinophilic myelodysplasia transforming to acute lymphoblastic leukaemia.. Journal of Clinical Pathology. 52(5). 388–389. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact